| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.003 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.099 | 0.009 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.02 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.02 |